COMP <GO>
MRNA vs RVMD // REVENUE GROWTH (YOY)
Moderna Inc. (NASDAQ) VS. Revolution Medicines Inc. (NASDAQ) • 15-METRIC TALLY: MRNA 4
— RVMD 4
▲ REVENUE GROWTH (YOY) LEADER: RVMD
LAST: $222.76 (+4.01%) • MKT CAP: $88.93B
revenue-growth
-39.90%
LAST: $190.27 (+0.82%) • MKT CAP: $40.78B
revenue-growth
15.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MRNA VS. RVMD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MRNA | RVMD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 55.30% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -34.10% | -28.60% | -5.50 | RVMD | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.32% | -2.24% | -0.08 | RVMD | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | -39.90% | 15.40% | -55.30 | RVMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 15.07 | 26.00 | -10.93 | RVMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 5/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.7 | 47.8 | +9.90 | MRNA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 1.07 | +0.03 | MRNA | /macro-sensitivity <GO> |
| Forward P/E Multiple | 32.0x | 34.0x | -2.00 | MRNA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $88.93B | $40.78B | $48.15B | MRNA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MRNA REV | RVMD REV | MRNA GROSS % | RVMD GROSS % | MRNA FCF | RVMD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.94B | $0 | 55.3% | — | -$2.06B | -$913.7M |
| FY 2024 | $3.24B | $0 | 54.8% | — | -$4.05B | -$567.7M |
| FY 2023 | $6.85B | $11.6M | — | — | -$3.43B | -$351.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MRNA // BETA 1.10
RVMD // BETA 1.07